Agilent bioanalyser, LabChip kits and Pierce protein-related kits offer biochemists better tools for research
Pierce Biotechnology and Agilent Technologies have announced a co-marketing agreement involving the Agilent 2100 bioanalyser, Protein 200 Plus, and Protein 50 LabChip kits and Pierce protein reagents and consumables.
The combination of these products enable molecular biologists and biochemists analysing proteins to obtain higher quality results faster in their disease research. Since the technology's introduction three years ago, the Agilent 2100 bioanalyser and LabChip kits, jointly developed with Caliper Technologies, have been established as the market-leading microfluidics-based system for analysing RNA, DNA, protein and cell fluorescence.
More than 1,800 bioanalysers have been sold to date.
The LabChip kits measure both sample quality and quantity in one step.
Pierce is a leading provider of reagents and consumables used in proteomics and protein analysis.
The initial co-marketing activities between Agilent and Pierce will focus on protein application areas in which both companies have existing products that can be combined to deliver better solutions to customers.
"Pierce has a very strong product portfolio, brand and market position in the protein analysis segment of the life sciences industry," said Karlheinz Bruederle, vice president and general manager of the Pharmaceutical Solutions Unit in Agilent's Life Science and Chemical Analysis business.
"Numerous Pierce products allow efficient protein purification or protein sample clean-up.
The co-marketing activities will allow us to show customers how they can get superior and faster results using Pierce products prior to analysing samples on the 2100 bioanalyser." "The Agilent 2100 bioanalyser can better measure sample quality and quantity than conventional techniques such as SDS-Page," said Ted DeFrank, vice president and general manager of Pierce Biotechnology.
"We plan to use the bioanalyser to show that our Pierce brand products meet our customers' stringent quality needs.
Pierce views microfluidics as an increasingly important technology for the analysis of biological samples. Partnering with Agilent, the leader in microfluidics, provides Pierce with the opportunity to further enhance our market-leading position in protein analysis and proteomics." As part of the co-marketing agreement, the two companies will develop a series of scientific application notes that describe challenging or novel applications that can be more easily accomplished or yield better results using the combination of Agilent and Pierce products.
